Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

Degenhardt, Thorsten P; Alderson, Nathan L; Arrington, David D; Beattie, Robert J; Basgen, John M; Steffes, Michael W; Thorpe, Suzanne R; Baynes, John W

Degenhardt, Thorsten P; Alderson, Nathan L; Arrington, David D; Beattie, Robert J; Basgen, John M; Steffes, Michael W; Thorpe, Suzanne R; Baynes, John W.

Affiliation

Degenhardt TP; Department of Chemistry, Animal Resource Facility, University of South Carolina, Columbia, SC 29208, USA.

Kidney Int ; 61(3): 939-50, 2002 Mar.

Article in En | MEDLINE | ID: mdl-11849448

Subject(s)

Diabetes Mellitus, Experimental/complications; Diabetic Nephropathies/prevention & control; Hyperlipidemias/etiology; Hyperlipidemias/prevention & control; Pyridoxamine/pharmacology; Animals; Collagen/metabolism; Diabetes Mellitus, Experimental/physiopathology; Diabetic Nephropathies/pathology; Diabetic Nephropathies/physiopathology; Disease Progression; Female; Glycation End Products, Advanced/metabolism; Guanidines/blood; Guanidines/urine; Hyperlipidemias/pathology; Hyperlipidemias/physiopathology; Lipid Metabolism; Oxidation-Reduction; Pyridoxamine/blood; Pyridoxamine/urine; Rats; Rats, Sprague-Dawley

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyridoxamine / Diabetes Mellitus, Experimental / Diabetic Nephropathies / Hyperlipidemias Limits: Animals Language: En Journal: Kidney Int Year: 2002 Document type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links